Rabobank: Its way too early to draw conclusions However, Nick Fereday, senior analyst, consumer foods at Rabobank, says we should be careful about making sweeping predictions about the future of the food industry based on preliminary survey data from a relatively small number of GLP-1 drug users
Our Score: 4/5 Our Score: 4/5 Our score is based on the latest data, customer feedback, clinical transparency, and ease of patient onboarding
For a customers-eye view, read Peak Wellness reviews on Trustpilot
The low-frequency non-synonymous A316T (rs10305492) variation in the GLP1R coding sequence is associated with lower fasting glucose levels and reduced risk of type 2 diabetes, but it is accompanied by a weakened insulin response to glucose challenge, reduced insulinogenic index, and increased 2-hour postprandial glucose levels
Studies also show that results can last for two years or more when treatment continues